Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys

Yumei Xiong1, Kenneth Walker2, Xiaoshan Min3

  • 1Department of Cardiometabolic Disorders, Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA.

Insights

Growth differentiation factor 15 (GDF15) shows promise as an obesity treatment. GDF15 Fc fusion proteins effectively reduced body weight and improved metabolic health in preclinical models.

Area of Science:

  • Metabolic research
  • Endocrinology
  • Obesity therapeutics

Background:

  • Obesity is a complex metabolic disorder with limited effective treatments.
  • Identifying metabolically regulated secreted proteins is crucial for therapeutic development.

Purpose of the Study:

  • To investigate the role of macrophage inhibitory cytokine 1 (MIC-1)/growth differentiation factor 15 (GDF15) in metabolic regulation.
  • To develop novel GDF15-based therapeutics for obesity and related conditions.

Main Methods:

  • Microarray analysis of gene expression in metabolic tissues of lean and obese mice.
  • Administration of adeno-associated virus-mediated GDF15 and recombinant GDF15 in preclinical models.
  • Structure-guided design and generation of GDF15 Fc fusion proteins.
  • Assessment of GDF15's effects on gastric emptying, food preference, and neuronal activation.

Main Results:

  • Elevated circulating GDF15 levels were observed in obese mice, rats, and humans.
  • GDF15 treatment reduced food intake, body weight, and improved metabolic profiles.
  • Novel Fc fusion molecules of GDF15 demonstrated extended half-life and potent efficacy.
  • GDF15 was found to influence the gut-brain axis by delaying gastric emptying and activating specific neurons.

Conclusions:

  • GDF15 plays a significant role in regulating energy intake and body weight.
  • GDF15 Fc fusion proteins represent a promising therapeutic strategy for obesity and its comorbidities.

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.0K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
310
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
210
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
298